Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Amazon Great Indian Festival 2020 - Electronics
Research

| More

Zydus Cadila receives US FDA approval - Angel Broking

Posted On: 2020-09-24 23:55:27


Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd

Zydus Cadila has received final approval from the USFDA to market Dimethyl Fumarate DelayedRelease Capsules, (US RLD: Tecfidera®) in the strengths of 120 mg and 240 mg. In its approval, the USFDA noted that Zydus was one of the first ANDA applicants to submit a substantially complete ANDA and is therefore eligible for 180 days of generic drug exclusivity along with other first ANDA applicants. Dimethyl Fumarate Delayed-Release Capsules are indicated for the treatment of patients with relapsing forms of multiple sclerosis and will be manufactured at the group's manufacturing facility at the SEZ, Matoda. Company now has 303 approvals and has so far filed over 390 ANDAs. This is a positive development for Zydus Cadila.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.376.05 as compared to the previous close of Rs. 383.9. The total number of shares traded during the day was 110488 in over 2727 trades.

The stock hit an intraday high of Rs. 383.8 and intraday low of 373.95. The net turnover during the day was Rs. 41874067.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com

Amazon Great Indian Festival 2020 - Mobiles


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Reiterate ADD on Amara Raja Batteries - Pent-up demand leads to healthy 2Q - HDFC Securities

Maintain REDUCE on Titan - Reasonable print - HDFC Securities

REDUCE on RBL Bank - Some positives, but key concerns remain - HDFC Securities

Maintain REDUCE on Marico - Saffola shines with PCNO recovery, muted margin - HDFC Securities

Maintain ADD on Dr. Reddy's Labs - Good quarter, lower SG&A cost is encouraging - HDFC Securities

Piramal Enterprises - Acquisition of stake from JV partner - Angel Broking

Maintain BUY on Axis Bank - Provision buffers strengthened (further) - HDFC Securities

AU Small Finance Bank - Q2FY21 Result - Angel Broking

L&T - Q2FY21 - Angel Broking

RBL Bank - Q2FY21 Result - Angel Broking

Axis Bank - Q2FY21 Result - Angel Broking

Marico Ltd - Q2FY21 Result Update - YES Securities

Titan Company Ltd - Q2FY21 Result Update - YES Securities

Axis Bank Limited - Q2FY21 Result Update - YES Securities

RBL Bank Limited - Q2FY21 Result Update - YES Securities

Multi Commodity Exchange of India - Operating leverage aids strong EBITDA performance - ICICI Securities

Titan Company - Faster-than-expected recovery - ICICI Securities

Marico - Strong performance across portfolio - ICICI Securities

Heritage Foods - Lower procurement prices leading to highest EBITDA margin in past decade - ICICI Securities

Axis Bank - Strong core again utilised to create provisioning buffer - ICICI Securities

Supreme Industries - Beat on all counts - ICICI Securities

GSK Pharmaceuticals - Recovery from COVID-19 impact - ICICI Securities

Hero MotoCorp - Solid demand recovery expectations priced in - ICICI Securities

Cement - Demand / prices improve further in Oct'20 - ICICI Securities

CEAT - Replacement demand drives outperformance - ICICI Securities

Dr. Reddy's Laboratories - Outperformance continues - ICICI Securities

ICICI Prudential Life Insurance - VNB trajectory in-line despite YoY dip in protection in Q2 - ICICI Securities

Bharti Airtel - Q2FY21 Result Update - ICICI Securities

Marico - Q2FY21 Result Update - ICICI Securities

Larsen & Toubro - Q2FY21 First Cut - ICICI Securities

Sanofi India - Q3CY20 Company Update - ICICI Securities

Adani Ports and SEZ - Quant Pick - ICICI Securities

Nippon Life India AMC - Q2FY21 Result Update - ICICI Securities

Tata Motors - Q2FY21 Result Update - ICICI Securities

Derivatives Strategy - Mahanagar Gas - Positional Future - ICICI Securities

Supreme Industries - Q2FY21 First Cut - ICICI Securities

Dr Reddy's Laboratories - Q2FY21 First Cut - ICICI Securities

Marico Ltd - Q2FY21 First Cut - ICICI Securities

Apcotex Industries - Q2FY21 First Cut - ICICI Securities

V-Guard Industries - Q2FY21 First Cut - ICICI Securities

Titan Company - Q2FY21 First Cut - ICICI Securities

Navin Fluorine - Q2FY21 First Cut - ICICI Securities

PI Industries - Q2FY21 First Cut - ICICI Securities

L&T - Q2FY21 Earnings First Cut: Beat on EBITDA margins - YES Securities

Bharti Airtel - Q2FY21 result - Angel Broking

Dr.Reddy's Lab - Q2FY21 - Angel Broking

BUY on Mahindra & Mahindra Financial Services - Remains an inexpensive rural play - HDFC Securities

Radico Khaitan - Q2FY21 - Angel Broking

Maintain BUY on CDSL - Firing on all cylinders - HDFC Securities

REDUCE on Nippon Life India Asset Management - Market share stabilising - HDFC Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019